Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.
J Mol Endocrinol. 2011 Nov 2;47(3):R91-103. doi: 10.1530/JME-11-0023. Print 2011 Dec.
This review describes the gene expression profile changes associated with the presence of different mutations that contribute to thyroid cell carcinogenesis. The results are discussed in the context of thyroid cancer biology and of the implications for disease prognosis, while the diagnostic aspect has been omitted. For papillary thyroid cancer (PTC), the most characteristic gene expression profile is associated with the presence of BRAF mutation. BRAF-associated PTC differ profoundly from RET/PTC or RAS-associated cancers. Simultaneously, they retain many characteristic gene expression features common for all PTCs, induced by the alternative mutations activating MAPK pathway. Although the difference between papillary and follicular thyroid cancer (FTC) is significant at the gene expression profile level, surprisingly, the RAS-related signature of FTC is not well specified. PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements, which occur in FTC as an alternative to the RAS mutation, are associated with specific changes in gene expression. Furthermore, the difference between well-differentiated thyroid cancers and poorly differentiated and anaplastic thyroid cancers is mainly a reflection of tumor degree of differentiation and may not be attributed to the presence of characteristic mutations.
这篇综述描述了与导致甲状腺细胞癌发生的不同突变相关的基因表达谱变化。讨论的结果是在甲状腺癌生物学和对疾病预后的影响的背景下进行的,而诊断方面则被省略了。对于甲状腺乳头状癌 (PTC),最典型的基因表达谱与 BRAF 突变的存在有关。BRAF 相关的 PTC 与 RET/PTC 或 RAS 相关的癌症有很大的不同。同时,它们保留了许多由 MAPK 通路激活的替代突变诱导的所有 PTC 的共同特征基因表达特征。尽管在基因表达谱水平上,甲状腺乳头状癌和滤泡状甲状腺癌 (FTC) 之间存在显著差异,但令人惊讶的是,FTC 的 RAS 相关特征并不明确。FTC 中发生的替代 RAS 突变的 PAX8/过氧化物酶体增殖物激活受体 γ (PPARγ) 重排与基因表达的特定变化相关。此外,分化良好的甲状腺癌与低分化和间变性甲状腺癌之间的差异主要反映了肿瘤的分化程度,而不能归因于特征性突变的存在。